News Focus
News Focus
icon url

BTH

08/17/11 1:19 PM

#125230 RE: DewDiligence #125229

With Zelboraf as a melanoma treatment, assuming Vismodegib gets approval for inoperable BCC (also going in operable BCC in earlier stages), Roche will have a nice niche in the skin cancer segment.
icon url

masterlongevity

08/17/11 7:45 PM

#125264 RE: DewDiligence #125229

I think genentech and Novartis are still the top 2, with BMY 3rd and PFE 4th... at least in terms of innovation